Department of Pharmacy, Nangrong Hospital, Buriram, Thailand.
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
Curr Drug Saf. 2021;16(3):296-298. doi: 10.2174/1574886315666201217095950.
A rare type of cutaneous adverse drug reaction (CADR), lichenoid drug eruption (LDE), can be associated with ethambutol.
A 60-year-old woman with spinal tuberculosis received multiple anti-TB medications and developed rashes after 3 months of the treatments. A skin biopsy from the posterior auricular area confirmed lichenoid dermatitis, and the Naranjo causality assessment indicated ethambutol as a probable cause of LDE in the patient. The rashes slowly improved after discontinuation of ethambutol. Unfortunately, the residual of brown hyperpigmentation on the body still persisted for over 16 months.
The medications were reduced to isoniazid 300 mg/day and rifampicin 450 mg /day as planned for another 3 months. This case report points out the essentials of early recognition of ethambutol LDE by health care professionals.
一种罕见的药物不良反应（CADR），即苔藓样药物疹（LDE），可能与乙胺丁醇有关。
一名 60 岁女性患有脊椎结核，接受了多种抗结核药物治疗，在治疗 3 个月后出现皮疹。耳后区域的皮肤活检证实为苔藓样皮炎，Naranjo 因果关系评估表明乙胺丁醇是导致该患者 LDE 的可能原因。停用乙胺丁醇后，皮疹逐渐改善。不幸的是，身体上的褐色色素沉着残留仍持续了 16 个月以上。
按照计划，将药物减少至异烟肼 300 mg/天和利福平 450 mg/天，再治疗 3 个月。本病例报告指出了医疗保健专业人员早期识别乙胺丁醇 LDE 的要点。
